AstraZeneca new crown vaccine press pause button Kangtai biology: individual cases are normal, does not affect cooperation

According to reports, on September 8 local time, AstraZeneca, a British pharmaceutical company, announced that it would suspend the third phase global clinical trial of the covid-19 vaccine azd1222 (chadox1) due to an unexplained disease in a British volunteer. < / P > < p > as one of the fastest-growing companies in the world in the research and development of covid-19 vaccine, AstraZeneca suspended clinical trials in the final sprint stage, causing high market attention. Affected by this, AstraZeneca fell 8% after the day on September 8. Kangtai bio (300601, SZ; yesterday’s closing price was 162 yuan), which had previously reached the exclusive authorization cooperation with AstraZeneca on the new crown vaccine in the mainland of China. The share price of Kangtai biological Co., Ltd. fell sharply on September 9, with a drop of more than 19% during the session and 16.57% at the end of the day. < p > < p > at the noon of September 9, Kang Tai bio Dong Mi Miao gave an exclusive response to the reporter of the daily economic news, saying that AstraZeneca is the leading company in the world’s new crown vaccine research and development company, with the largest scale of trials. The occurrence of individual cases is a normal phenomenon in research and development, which does not affect the promotion of cooperation between the company and AstraZeneca. The market may have misunderstood this incident. At the same time, AstraZeneca also told reporters that a standard audit process has been initiated for the ongoing global randomized control group trial of Oxford University’s new coronavirus vaccine. At present, there is indeed a “voluntary suspension of vaccination to ensure that the safety data of the vaccine are verified by the independent commission”. It is understood that azd1222 (chadox1) is a covid-19 vaccine jointly developed by Oxford University and its derivative company vaccititech. It uses a replication defective chimpanzee virus vector based on a weakened version of the common cold virus (adenovirus). The virus causes infection in chimpanzees and contains genetic material for the spike protein of the new coronavirus. After vaccination, the immune system will recognize the surface spike protein, causing the immune system to attack the new coronavirus invading the human body. < / P > < p > among the dozens of vaccines being developed around the world, azd1222 (chadox1) has always been regarded as a strong competitor. On April 23 this year, azd1222 (chadox1) officially launched a phase I clinical trial. As of July 1, more than 8000 volunteers participated in the randomized controlled clinical trial to evaluate the safety of the vaccine. In May, AstraZeneca established a partnership with Oxford University to develop, produce and supply the new crown vaccine azd1222 (chadox1) worldwide. AstraZeneca promised to provide more than 2 billion doses of new crown vaccine. < / P > < p > two months later (July), the interim results of phase I and phase II cov001 trials were published in the lancet, which showed that azd1222 (chadox1) could be tolerated by human body, and produced a strong immune response against NCV in all participants. Since then, the expectation that azd1222 (chadox1) vaccine will become the first batch of vaccine on the market is even higher.

in August 31st, novel coronavirus pneumonia AZD1222 (ChAdOx1) entered the three phase clinical trial by AstraZeneca official website. 30000 adults aged 18 or above were recruited in the United States to conduct experiments to assess their safety, efficacy and immunogenicity. In addition, the clinical development of azd1222 (chadox1) is also advancing globally, with late clinical trials in the UK, Brazil and South Africa, and trials are planned to start in Japan and Russia. Up to 50000 participants were recruited worldwide to provide data for people of different races. Before that, azd1222 (chadox1) vaccine had been ordered by many countries. Novel coronavirus pneumonia has been signed by the European Union’s executive board on August 27th, according to Reuters. The European Union’s Executive Board will sign a contract with AstraZeneca, a British pharmaceutical manufacturer, who will supply at least 30 million doses of new crown vaccine. The British government announced in June that it would buy 100 million doses of AstraZeneca vaccine. Germany, France, Italy and the Netherlands formed a “vaccine alliance” in June, signing an agreement with AstraZeneca, which has scheduled 400 million doses of vaccine. Novel coronavirus pneumonia,

, was also announced in August 19th. The Australian government has signed a letter of intent with the British AstraZeneca pharmaceutical company. Once the new crown pneumonia vaccine AZD1222 (ChAdOx1) is proved to be safe and effective, Australia will produce the vaccine in its own country. Japan’s Ministry of health, health and labor is making final arrangements to ensure that at least 100 million doses of potential new crown vaccine are available from AstraZeneca, the Japan Economic News reported on August 6. The supply will be enough to meet the demand of at least 50 million people. On the Chinese side, on August 6, AstraZeneca announced that it had signed an exclusive licensing cooperation framework agreement with the domestic vaccine giant Kangtai bio in the mainland of China, and actively promoted the R & D, production, supply and commercialization of the adenovirus vector new crown vaccine azd1222 (chadox1) cooperated by AstraZeneca and Oxford University in the Chinese mainland market through technology transfer. < p > < p > the new epidemic situation has a great impact on the global economy and life. Novel coronavirus pneumonia confirmed 203897 new cases in the world and 9566 new deaths in September 8th. The most serious cases in the Americas region reached 14193356 (75644 new cases) and 494145 deaths (7302 new cases).

novel coronavirus pneumonia is on the horizon, and AZD1222 (ChAdOx1) is pressed to “pause” when countries are looking forward to the new crown pneumonia vaccine. AstraZeneca announced on September 8 that it would suspend the third phase of the global azd1222 (chadox1) clinical trial because of an unexplained disease in a British volunteer. As part of an ongoing global randomized trial of the new coronavirus vaccine, our standard review procedure resulted in a suspension of vaccination in order to review safety data, AstraZeneca said in a statement. This is a routine behavior. In the process of investigation, once a potential disease of unknown origin appears in a certain trial, it must be taken to ensure the integrity of the experiment. < p > < p > AstraZeneca stressed: “in large-scale trials, diseases occur occasionally, but they must be independently reviewed and carefully examined. We are working to speed up the review of individual events to minimize any potential impact on the test schedule. We are committed to the safety of participants and to the highest standards of conduct in the trials. “. At noon on September 9, Beijing time, AstraZeneca told the daily economic news that a standard audit process had been initiated for the ongoing global randomized control group trial of Oxford University’s new coronavirus vaccine. At present, there is indeed a “voluntary suspension of vaccination to ensure that the safety data of the vaccine are verified by the independent commission”. < / P > < p > in the above Chinese response, there was no further explanation on the details of vaccine trial safety events, such as which step of the trial the rumored “adverse reaction” appeared, and what specific adverse reactions the trial participants had. < / P > < p > affected by the news that azd1222 (chadox1) clinical trial was suspended, AstraZeneca’s share price fell 8% after the day’s trading, while the shares of US aviation stocks and cruise stocks also fell, while the shares of vaccine development competitors such as Moderna Inc and biontech se rose. < / P > < p > on August 6, this year, AstraZeneca and Kangtai bio signed an exclusive licensing cooperation framework agreement in the mainland of China. Kangtai bio will promote the R & D, production, supply and commercialization of azd1222 (chadox1) in the Chinese mainland market through technology transfer. < / P > < p > according to the announcement of Kangtai biology, after the signing of the agreement, AstraZeneca will pay the license fee according to the agreement. The company has the sole right to develop licensed products in the mainland of China. It is responsible for conducting clinical trials required for regulatory approval in the region, and is responsible for all communication with regulatory authorities. AstraZeneca shall perform technology transfer, deliver technology transfer data and provide technical support in accordance with the terms sheet and the transaction agreement. < / P > < p > Kangtai Bio said that the company would have sufficient capacity to produce at least 100 million doses per year by the end of 2020 and at least 200 million doses per year by the end of 2021. At the same time, Kangtai bio also pointed out that the results of vaccine research and development and the progress of product marketing were uncertain. As the company has not officially produced and sold new crown vaccine products in the market, it is faced with certain uncertainty in the process of project construction and customer expansion, which may lead to the risk that the project construction progress is not as expected and the new capacity can not be digested in time. Kangtai biological was established in 1992 and is a leading enterprise in the domestic vaccine industry. Its hepatitis B vaccine has occupied more than 50% of the Chinese market for a long time. Affected by the new crown epidemic, at the beginning of this year, Kangtai biological stock price has been rising. At the end of May this year, Du Weimin, the actual controller of Kangtai biological, announced the dissolution of his marriage and the division of his property. According to the stock price calculation on the day of the announcement, Yuan Liping, his ex-wife, gained a market value of 23.5 billion yuan, which directly broke the record of “skyrocketing separation fee” in the A-share market. < / P > < p > after a brief correction at the end of May, Kangtai bio’s share price continued to soar. On August 4, Kangtai bio reached a record high of 249.69 yuan / share, nearly doubled compared with the end of May and increased by more than 180% compared with the beginning of the year. Today, Kangtai biology is a member of the “100 billion market value club”. < / P > < p > since the beginning of August, domestic vaccine concept stocks have begun to callback. Although Kangtai biological disclosed the exclusive authorized cooperation with AstraZeneca, its share price continued to fall. Affected by the news that AstraZeneca azd1222 (chadox1) clinical trial was suspended, Kangtai biological closed at 162 yuan / share on September 9, down 16.57%. < p > < p > at the noon of September 9, Kang Tai bio Dong Mi Miao gave an exclusive response to the reporter of the daily economic news, saying that AstraZeneca is the leading company in the world’s new crown vaccine research and development company, with the largest scale of trials. The occurrence of individual cases is a normal phenomenon in research and development, which does not affect the promotion of cooperation between the company and AstraZeneca. The market may have misunderstood this incident. However, the concept of A-share biological vaccine still suffered a heavy setback on the 9th. As of the end of the day, Zhifei biological Co., Ltd. fell 11.91%, Wantai bio and Haili bio Co., Ltd. fell by more than 8%. < / P > < p > Disclaimer: the purpose of this article reprinted by china.com finance and economics is to convey more information and does not represent the views and positions of the website. The content of this paper is for reference only and does not constitute investment advice. Investors operate accordingly and bear their own risks. < p > < p > Chinanet is a national key news website under the leadership of the Information Office of the State Council and managed by China foreign language publishing and Distribution Bureau. Through 11 versions in 10 languages, the website releases information 24 hours a day, which is an important window for China to carry out international communication and information exchange.